{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-019381","form_type":"8-K","ticker":"INTI","cik":"0001042418","company_name":"Inhibitor Therapeutics, Inc.","filed_at":"2025-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.635017+00:00","generated_at":"2026-05-17T02:08:13.789704+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Inhibitor Therapeutics enters Frameshift consulting pact for Gorlin syndrome; 18M warrants possible","bullets":["Entered Master Services Agreement with Frameshift Management for biostatistics, regulatory, and business development support for itraconazole program in Gorlin's syndrome.","Performance-based compensation includes up to 18 million unvested 4-year warrants, vesting upon milestones such as FDA approval or sale of program.","First SOW involves re-analysis of HP2001 clinical study data and preparing FDA meeting request (Type B/C/D).","Board adopted 2025 Equity Incentive Plan reserving 20 million shares; subject to shareholder approval within 12 months.","Consulting agreement continues indefinitely; each project governed by separate SOWs."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-019381","json":"https://secwatch.observer/filing/0001493152-25-019381.json","markdown":"https://secwatch.observer/filing/0001493152-25-019381.md","text":"https://secwatch.observer/filing/0001493152-25-019381.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1042418/000149315225019381/0001493152-25-019381-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1042418/000149315225019381/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:08:13.789704+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}